Common Painkillers May Help Prevent Skin Cancer: Study

TUESDAY, May 29 (HealthDay News) — Taking nonsteroidal
anti-inflammatory drugs (NSAIDs) — which include medicine cabinet staples
such as aspirin, Motrin and Aleve — appears to significantly lower the
risk for developing several major forms of skin cancer, a new Danish study
reveals.

What’s more, the apparent protective impact of both prescription and
nonprescription NSAIDs on skin cancer risk seems to be stronger the longer
someone takes them.

Over-the-counter NSAIDs are used to control pain, fever and swelling.
NSAIDs also include prescription medicines called COX-2 enzyme inhibitors,
such as Celebrex (celecoxib).

“Our study showed that users of common painkillers, known as NSAIDs,
have a lower risk of the three major types of skin cancer, [including]
malignant melanoma, basal cell carcinoma and squamous cell carcinoma,”
said study lead author, Sigrun Alba Johannesdottir, at the department of
clinical epidemiology at Aarhus University Hospital in Aarhus,
Denmark.

“The greatest effect,” she noted, “was found for squamous cell
carcinomas and malignant melanoma, especially when [these painkillers
were] taken frequently and over a long time period.”

The study appears in the May 29 online issue of the journal
Cancer.

The authors noted that prior work supported the notion that NSAIDs may
offer some measure of protection against cancer (most notably colorectal
cancer), by specifically impeding the cancer-causing activities of COX-2
(cyclooxygenase) enzymes.

However, the team suggested that past investigations into how NSAIDs
may affect skin cancer risk, in particular, had key design problems that
undercut efforts to nail down any NSAID-skin cancer connection.

For the new study, the researchers analyzed prescription databases and
health information registries including the Danish Cancer Registry and the
Danish Civil Registration System.

The team focused on diagnostic and death records concerning nearly
2,000 cases of squamous cell carcinoma, about 13,300 cases of basal cell
carcinoma and nearly 3,250 cases of malignant melanoma diagnosed between
1991 and 2009 when the patients were at least 20 years old.

In turn, prescription histories were gathered for both the cancer
patient group and almost 179,000 healthy Danes. Records covered the use of
both low- and high-dose aspirin (ranging from 75 milligrams to 500
milligrams), so-called “nonselective” NSAIDs (such as ibuprofen [Advil]
and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.
Researchers noted the number of prescriptions issued per patient and their
length of use, with short-term use defined as fewer than seven years.

The result: The relative risk for squamous cell carcinoma was found to
have dropped by 15 percent among those Danes who had filled more than two
NSAID prescriptions, compared to those who had filled two or less.

Similarly, malignant melanoma risk fell by nearly as much (13 percent)
among those filling more than two NSAID prescriptions.

However, the same dynamic was generally not seen with regards to
basal cell carcinoma. But taking NSAIDs for long periods of time, and at
relatively high doses, was associated with a reduced risk (between
15 and 21 percent), specifically for basal cell cases that manifested in
skin regions that typically experience relatively little sun exposure
(areas other than the neck or head).

On that front, long-term users and those who took NSAIDs at relatively
higher doses appeared to benefit from the strongest protective effect,
suggesting that when it comes to skin cancer risk reduction, more NSAID
use is better.

The researchers pointed out that the NSAID-cancer connection could be
affected by a range of lifestyle factors they did not account for, such as
an individual’s specific skin type or sun exposure patterns.

But Johannesdottir added that “we hope that our finding will inspire
more research on skin cancer prevention. Also, the potential
cancer-protective effect should be taken into account when discussing
benefits and harms of NSAID use,” she noted.

However, “other studies need to detail the association further and to
examine benefits versus risks,” she cautioned. “Meanwhile, the most
important prevention against skin cancer remains sun protection.”

Meanwhile, Dr. William Ting, a private practice dermatologist in San
Ramon, Calif., praised the study despite agreeing that many factors are at
play when it comes to skin cancer formation.

“Now we have a better understanding that inflammation also plays a
significant role in cancer formation and even skin cancers,” he said.

And, “this exciting article gives physicians and consumers a relatively
simple way of diminishing one’s risk of skin cancer by doing what most of
us are doing already for heart health,” Ting added. Ting also advised that
people consult with their doctor before starting on any blood thinner.

While the study found an association between skin cancer risk and
NSAIDs, it did not prove a cause-and-effect relationship.

More information

For more on NSAIDs and cancer, visit the U.S. National Cancer Institute.

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

Powered by WordPress | Designed by: Premium WordPress Themes | Thanks to Themes Gallery, Bromoney and Wordpress Themes